Витапрост форте свечи инструкция по применению
Vitaprost Plus sf equivalent dose of exendin-4 described herein is from about 1. Patent Application No. Patent No. Proalkyl and N. Patent Application Publication No. And X32 is Arg or absent. Sar 1,7 -Val 5 - vitaprost Plus sf I. Using synthetic protease-resistant peptide sequences disclosed in International Application No.
Ala, Leu, norleucine. J Pept Res Therefore, while the present invention include derivatives having polypeptide or extended polypeptide described herein, it is desirable the extension does not destroy the cell targeting activity of the polypeptide or derivative thereof. Chem, Int. USA; Zuckermann et al J. Med Chem Science Angew Chem, Int Vitaprost Plus sf. England as above ; and Gallop et al Med Chem vitaprost Plus sf, To be estimated.
Patent Nos. Patent application Publication No. HCl pH 2. Calculated as BloodFlow Metab. Patent Publication No. Moc 9- fluorenyl methoxycarbonyl amino-terminus protection, for SPPS. NT-solution vitaprost Plus sf, PBS 3. In the PBS 4x 2. Was dissolved in PBS 4x pH 7. IN solution. OmM, pH 7.
IN solution, the pH of the reaction was adjusted from 5. After 1 hour vitaprost Plus sf repeated. OmM, pH 6. IN NaOH solution. Application No. The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood- brain barrier or into particular cell types, X is a linker, and B is a peptide therapeutic.
The compounds of the invention can be used to treat any disease vitaprost Plus sf which the peptide therapeutic is useful. A compound according to claim 1, wherein the peptide is selected from the group consisting of an antimicrobial peptide or antimicrobial peptides, gastrointestinal peptides, pancreatic peptide, peptide hormones, hypothalamic hormones, pituitary hormones, neuropeptides, and the group consisting vitaprost Plus sf therapeutic agents.
A compound as claimed in any one of the preceding claims, wherein, X has the formula:. The compound according to claim 7, wherein, [eta] is a 3,6, or Vitaprost Plus sf compound according to claim 1, wherein, X is a peptide bond. The compound according to claim 1, wherein, X is at least one amino acid; and A and B by peptide bonds are each covalently bonded to X.
A method of preparing compound 9 or claim 10, said method comprising expressing a polypeptide encoded by a vector according to claim 12 in a cell, and purifying the polypeptide. A method of preparing compound 9 or claim 10, the method comprising synthesizing the compound on a solid support.
A method of treating a subject suffering from metabolic diseases, the method comprising in an amount sufficient to treat the disease administering the compound according to claim any one of claims 1 to The method according to claim 15, wherein the metabolic disease vitaprost Plus sf diabetes, obesity, obesity as a result of diabetes, hyperglycemia, dyslipidemia, hypertriglyceridemia, X syndrome, insulin resistance, impaired glucose tolerance IGTdiabetic dyslipidemia, hyperlipidemia, cardiovascular disease, or hypertension.
The method of vitaprost Plus sf 15, wherein the disease is diabetes. The method of claim 19, wherein the disease is type II diabetes. The method of claim 15, wherein the disease is obesity. The method according to claim 22, wherein the subject is overweight or obese. The method of claim 22, wherein the subject is bulimia. A method of treating or preventing a disease, the disease is selected from anxiety, movement disorders, aggression, psychosis, seizures, panic attacks, hysteria, sleep disorders, Alzheimer's disease, Parkinson's disease as well as the composition of the group, said method comprising an amount sufficient to treat or prevent said disease a compound according to any one of claims according to claim administering to a subject O.
A method of increasing neurogenesis in the treatment of a subject, said method comprising administering to said subject an effective amount of a vitaprost Plus sf according to any one of claims. The method of claim sink, wherein the subject is suffering from Parkinson's disease, Alzheimer's disease, Huntington's disease, ALS, stroke, ADD, or neuropsychiatric syndromes.
The method of claim sink, wherein said neurogenesis increasing or improving learning enhanced neuroprotection in said subject. A method of treating cancer in a subject, neuropathy, or lysosomal storage disease in a subject, said method comprising sufficient to treat the cancer, the amount of the disease, disorder, or any of the claims administering a compound according to the subject. The method according to claim 31, wherein said cancer is selected from astrocytoma, astrocytoma cells fiber, dysembryoplastic neuroepithelial tumor, oligodendrogliomas, ependymomagliomas, glioblastoma multiforme tumor, mixed glioma, astrocytoma less, medulloblastoma, retinoblastoma, neuroblastoma, germ cell tumors, and abnormal tire group consisting of tumors.
The method according to claim 30, wherein the cancer is selected from the group consisting of hepatocellular carcinoma, breast cancer, head and neck vitaprost Plus sf, including various lymphomas such as mantle cell lymphoma, non-Hodgkin's lymphoma, adenoma, vitaprost Plus sf cell carcinoma, laryngeal cancer, retina cancer, esophageal cancer, multiple myeloma, ovarian cancer, uterine cancer, melanoma, colorectal cancer, bladder cancer, prostate cancer, lung cancer including non-small cell lung cancer cancer, pancreas cancer, cervical cancer, head and neck cancer, skin cancer, nasopharyngeal carcinoma, liposarcoma, epithelial carcinoma, vitaprost Plus sf cell carcinoma, gallbladder adenocarcinoma, parotid adenocarcinoma, endometrial sarcoma, multidrug resistance and cancer.
The method according to claim 30, wherein the neuropathy selected from the group consisting of Alexander disease, Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis ALSataxia telangiectasia, bar vine disease Shi - Fu - homes - Batten diseasebovine spongiform encephalopathy BSECanavan disease, within Keke Kai syndrome, corticobasal degeneration, g - Jakob disease, Huntington's disease, associated with human immunodeficiency virus dementia, Kennedy's disease, Krabbe disease, Lewy body dementia, Ma - Joseph disease spinocerebellar ataxia type 3multiple sclerosis, multiple system atrophy, narcolepsy, nerve borreliosis, Parkinson's disease, Pelizaeus - Merzbacher disease, Pick's disease, primary lateral sclerosis, prion diseases, Refsum disease, Xie Boulder disease ie, adrenoleukodystrophyschizophrenia, spinocerebellar total ataxia, spinal muscular atrophy, Sri Lanka - in - Austria's disease, as well as the group consisting of spinal tuberculosis.
USP vitaprost Plus sf USA1 en. EPA1 en. JPA en. CNA en. AUA1 en. BRPIA2 en. CAA1 en. MXA en. RUA en. WOA1 en. ZAB en. PTE en. USB2 en. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues.
DKT4 en. CAC en. Treatment of ovarian cancer using an anticancer vitaprost Plus sf conjugated to an angiopep-2 analog. WOA2 en. Max-Planck-Gesellschaft zur Förderung der Wissenschaft e. Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders.
EPA2 en. Glycosylated peptides with pseudoproline residues and having enhanced half-lives and ability to cross the blood brain barrier. EPA4 en. Ph 7 injectable solution comprising at least one basic insulin including an inhibit of 5.
EST3 en. Mixed agonists based on GIP for the treatment of metabolic disorders and obesity. RUC2 en. TWIB en. KRB1 en. CNB en. JPB2 en. USA en. AUB2 en. EPB1 en. Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity.
Youn et al. Improved intestinal delivery of salmon calcitonin by Lysamine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy.